Dr Reddy's Laboratories (RDY) stock plummeted 5.10% during intraday trading on Tuesday, following the release of its quarterly financial results.
The pharmaceutical company reported quarterly earnings of $0.03 per share, which missed the analyst consensus estimate of $0.09 by 66.67 percent and represented an 86.36 percent decrease from the same period last year. Furthermore, quarterly sales of $821.821 million missed the analyst estimate of $866.120 million by 5.11 percent and marked a 17.49 percent decrease year-over-year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments